QR-1123
Phase 1/2Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autosomal Dominant Retinitis Pigmentosa
Conditions
Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Disease, Retinitis, Vision Tunnel, Vision Disorders
Trial Timeline
Oct 7, 2019 → Jun 7, 2022
NCT ID
NCT04123626About QR-1123
QR-1123 is a phase 1/2 stage product being developed by ProQR for Autosomal Dominant Retinitis Pigmentosa. The current trial status is active. This product is registered under clinical trial identifier NCT04123626. Target conditions include Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04123626 | Phase 1/2 | Active |
Competing Products
19 competing products in Autosomal Dominant Retinitis Pigmentosa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABBV-CLS-628 + Placebo | AbbVie | Phase 2 | 52 |
| AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B | AstraZeneca | Phase 1 | 33 |
| Placebo + Everolimus | Novartis | Approved | 85 |
| Octreotide + Placebo | Novartis | Phase 2/3 | 65 |
| Everolimus + Calcineurin inhibitors maintenance | Novartis | Phase 3 | 77 |
| Bosutinib + Bosutinib + Placebo | Pfizer | Phase 2 | 51 |
| VX-407 | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-407 + LNG/EE + NGM/EE + NET/EE + DRSP/EE | Vertex Pharmaceuticals | Phase 1 | 32 |
| VX-407 + Placebo + Midazolam + VX-407 | Vertex Pharmaceuticals | Phase 1 | 32 |
| VX-407 + Placebo | Vertex Pharmaceuticals | Phase 1 | 32 |
| Tesevatinib | Sanofi | Phase 1/2 | 40 |
| Tesevatinib + Placebo | Sanofi | Phase 2 | 51 |
| Venglustat + Placebo | Sanofi | Phase 2/3 | 64 |
| Bardoxolone methyl oral capsule + Placebo oral capsule | Biogen | Phase 3 | 74 |
| Lanreotide + saline | Ipsen | Phase 3 | 74 |
| KB105 | Krystal Biotech | Phase 2 | 49 |
| KB105 | Krystal Biotech | Phase 1/2 | 38 |
| Lixivaptan + Placebo | Centessa Pharmaceuticals | Phase 3 | 72 |
| GLPG2737 + Placebo | Galapagos | Phase 2 | 47 |